|
Date: 3 October 2023
Time: 11am - 12:30pm (followed by networking with lite bites) Panel discussion: "Emerging Trends in Biotech and What It Takes To Succeed" Format: Seminar (in-person; registration is required) Moderator: Natasha NG, IMCB & ExCo SCSS |
VENUE:
Matrix Building @Biopolis Level 2M Theatrette (Aspiration) 30 Biopolis St, Singapore 138671 |
As part of Stem Cell Society Singapore's (SCSS) Cell Therapy Focus Group (CTFG) monthly series in collaboration with IMCB A*STAR, we are excited to convene a panel discussion on Emerging Trends in Biotech and What It Takes To Succeed as our final event of the year! This discussion will come at an important juncture, in a year when we've seen both triumphs and losses locally and internationally in the cell therapy space. We hope to touch on sentiments and real-life experiences in the biotech cell therapy sector, hearing from representatives from investments, start up companies and industry players. This is with the goal of sharing with our scientific and entrepreneurial community some insights and considerations on translating research, being investment-ready, and how to make such ventures last. This event is also kindly supported by Merck Life Science.
Panelists' information
|
Kim PNG
Principal, Polaris Partners |
|
Bio
Kim is a principal at Polaris Partners. Based in Singapore, she is focused on healthcare investments and venture building globally. She currently serves on the Board of Directors for 65 Labs, a program that will accelerate the development of therapeutic technologies originating from Singapore institutions.
Prior to Polaris, Kim was an investment professional at Temasek, where she was responsible for healthcare investments into public and private equities globally.
Kim holds an MBA from Singapore Management University, a Ph.D. in Cancer Biology from Rockefeller University, and a B.S.E. in Biomedical Engineering from Duke University.
Kim is a principal at Polaris Partners. Based in Singapore, she is focused on healthcare investments and venture building globally. She currently serves on the Board of Directors for 65 Labs, a program that will accelerate the development of therapeutic technologies originating from Singapore institutions.
Prior to Polaris, Kim was an investment professional at Temasek, where she was responsible for healthcare investments into public and private equities globally.
Kim holds an MBA from Singapore Management University, a Ph.D. in Cancer Biology from Rockefeller University, and a B.S.E. in Biomedical Engineering from Duke University.
|
David LOONG
Head of Emerging Biotech (South Asia & Oceania), Merck Life Science |
|
Bio
David has many years of experience in the pharmaceutical industry spanning drug discovery and early-phase drug development. Prior to joining Merck, he held roles as scientist and consultant in biotech startups, contract research at AMRI Global (now Curia), and GMP manufacturing at GSK. His professional interests are on enabling strategies for process development and manufacturing during early clinical development, including cell and gene therapies. He holds a PhD in Organic Chemistry from the Australian National University (2004) and a Bachelor of Technology (Hons) in Chemical Technology from Massey University, New Zealand.
David has many years of experience in the pharmaceutical industry spanning drug discovery and early-phase drug development. Prior to joining Merck, he held roles as scientist and consultant in biotech startups, contract research at AMRI Global (now Curia), and GMP manufacturing at GSK. His professional interests are on enabling strategies for process development and manufacturing during early clinical development, including cell and gene therapies. He holds a PhD in Organic Chemistry from the Australian National University (2004) and a Bachelor of Technology (Hons) in Chemical Technology from Massey University, New Zealand.
|
Clare TAN
Tikva Allocell, Director of Clinical Operations and Project Management |
|
Bio
Clare is the Director of Clinical Operations and Project Management at Tikva Allocell. Tikva is a new cell therapy company that focuses on highly differentiated, enhanced, allogeneic EBV-specific T-cell platforms, targeting difficult-to-treat, unmet medical patient populations. It is headquartered in Singapore. She has been working in clinical operations and project management for 20 years. She was previously the Director of Global Clinical Operations at Tessa Therapeutics, where she managed global cell therapy studies, focusing on EBVSTs and CAR-T treatments in oncology disease across US, APAC and EU.
Prior to joining Tessa, Clare headed the Asia Pacific Early Clinical Development team in Labcorp to run Early Phase Immuno-Oncology, Rare Diseases and Epidemiology studies. She established alliance partnership with the key centres in the region and drive efficient clinical trial executions. Clare was also leading and growing the clinical operations team in Southeast Asia region during the earlier part of her career at PPD.
Clare is the Director of Clinical Operations and Project Management at Tikva Allocell. Tikva is a new cell therapy company that focuses on highly differentiated, enhanced, allogeneic EBV-specific T-cell platforms, targeting difficult-to-treat, unmet medical patient populations. It is headquartered in Singapore. She has been working in clinical operations and project management for 20 years. She was previously the Director of Global Clinical Operations at Tessa Therapeutics, where she managed global cell therapy studies, focusing on EBVSTs and CAR-T treatments in oncology disease across US, APAC and EU.
Prior to joining Tessa, Clare headed the Asia Pacific Early Clinical Development team in Labcorp to run Early Phase Immuno-Oncology, Rare Diseases and Epidemiology studies. She established alliance partnership with the key centres in the region and drive efficient clinical trial executions. Clare was also leading and growing the clinical operations team in Southeast Asia region during the earlier part of her career at PPD.
|
Christy MA
Chief Strategy Officer, SCG Cell Therapy |
|
Bio
Christy is the Chief Strategy Officer at SCG Cell Therapy Pte Ltd, a leading biotechnology company focusing on the development of novel immunotherapies in infections and its associated cancers. The company targets the most common cancer-causing infections: helicobacter pylori, human papillomavirus, and hepatitis B, and develops a broad and unique pipeline of TCR-T cell therapies, antibodies, and therapeutic vaccines against infections and to prevent and cure its associated cancers.
Christy specialties in oncology and immunotherapy drug development. Before joining SCG, she served in various positions in Clinical Development and Pharmacovigilance, with participation in the development of Talzenna® (talazoparib), Cabiralizumab in combination with Opdivo® (nivolumab), Herceptin® (trastuzumab) and Avastin® (bevacizumab).
Christy received her B.S. degree in Chemical Biology from University of California, Berkeley and holds her M.S. in Medical Product Development Management from San Jose State University.
Christy is the Chief Strategy Officer at SCG Cell Therapy Pte Ltd, a leading biotechnology company focusing on the development of novel immunotherapies in infections and its associated cancers. The company targets the most common cancer-causing infections: helicobacter pylori, human papillomavirus, and hepatitis B, and develops a broad and unique pipeline of TCR-T cell therapies, antibodies, and therapeutic vaccines against infections and to prevent and cure its associated cancers.
Christy specialties in oncology and immunotherapy drug development. Before joining SCG, she served in various positions in Clinical Development and Pharmacovigilance, with participation in the development of Talzenna® (talazoparib), Cabiralizumab in combination with Opdivo® (nivolumab), Herceptin® (trastuzumab) and Avastin® (bevacizumab).
Christy received her B.S. degree in Chemical Biology from University of California, Berkeley and holds her M.S. in Medical Product Development Management from San Jose State University.